PURPOSE: To compare the signal characteristics and bolus dynamics of 1.0 M gadobutrol and 0.5 M Gd-DTPA for time-resolved, three-dimensional, contrast-enhanced (CE) MRA of the upper torso. MATERIALS AND METHODS: Ten healthy volunteers were examined with time-resolved three-dimensional CE-MRA (scan time per three-dimensional data set: 0.86 second; voxel size: 3.6 x 2 x 6.3 mm(3)). Each volunteer underwent eight individual examinations after intravenous injection of 0.05 and 0.1 mmol/kg body weight (b.w.) of 1.0 M gadobutrol and 0.5 M Gd-DTPA using two injection rates (2.5 and 5 mL/second). The data analysis included quantitative measurements of the peak signal-to-noise ratio (SNR) and bolus dispersion (full width at half maximum (FWHM)) in the pulmonary artery, left atrium, and thoracic and abdominal aortas. RESULTS: No significant differences in the peak SNR and bolus dispersion were observed between gadobutrol and Gd-DTPA for all dose levels and injection rates in any of the vascular segments. For both contrast agents a dose of 0.1 mmol/kg b.w. injected with 5 mL/second achieved the highest SNR in all vascular segments. CONCLUSION: For the imaging parameters used in this study, higher-concentrated gadolinium chelates offer no relevant advantages for time-resolved three-dimensional CE-MRA of the upper torso. (c) 2005 Wiley-Liss, Inc.
PURPOSE: To compare the signal characteristics and bolus dynamics of 1.0 M gadobutrol and 0.5 M Gd-DTPA for time-resolved, three-dimensional, contrast-enhanced (CE) MRA of the upper torso. MATERIALS AND METHODS: Ten healthy volunteers were examined with time-resolved three-dimensional CE-MRA (scan time per three-dimensional data set: 0.86 second; voxel size: 3.6 x 2 x 6.3 mm(3)). Each volunteer underwent eight individual examinations after intravenous injection of 0.05 and 0.1 mmol/kg body weight (b.w.) of 1.0 M gadobutrol and 0.5 M Gd-DTPA using two injection rates (2.5 and 5 mL/second). The data analysis included quantitative measurements of the peak signal-to-noise ratio (SNR) and bolus dispersion (full width at half maximum (FWHM)) in the pulmonary artery, left atrium, and thoracic and abdominal aortas. RESULTS: No significant differences in the peak SNR and bolus dispersion were observed between gadobutrol and Gd-DTPA for all dose levels and injection rates in any of the vascular segments. For both contrast agents a dose of 0.1 mmol/kg b.w. injected with 5 mL/second achieved the highest SNR in all vascular segments. CONCLUSION: For the imaging parameters used in this study, higher-concentrated gadolinium chelates offer no relevant advantages for time-resolved three-dimensional CE-MRA of the upper torso. (c) 2005 Wiley-Liss, Inc.
Authors: Henrik J Michaely; Olaf Dietrich; Kambiz Nael; Sabine Weckbach; Maximilian F Reiser; Stefan O Schoenberg Journal: Eur Radiol Date: 2006-05-24 Impact factor: 5.315
Authors: Puja Shahrouki; Kim-Lien Nguyen; John M Moriarty; Adam N Plotnik; Takegawa Yoshida; J Paul Finn Journal: Br J Radiol Date: 2021-09-01 Impact factor: 3.629
Authors: Achim Seeger; Ulrich Kramer; Michael Fenchel; Florian Grimm; Christiane Bretschneider; Jörg Döring; Bernhard Klumpp; Gunnar Tepe; Kilian Rittig; Peter R Seidensticker; Claus D Claussen; Stephan Miller Journal: J Cardiovasc Magn Reson Date: 2008-12-30 Impact factor: 5.364
Authors: Ilkay Koray Bayrak; Zafer Ozmen; Mehmet Selim Nural; Murat Danaci; Baris Diren Journal: Korean J Radiol Date: 2008 May-Jun Impact factor: 3.500